| DIRECT COMPETITOR COMPARISON | |
| SNY | GSK | MRK | PFE | Industry | | Market Cap: | 102.75B | 107.59B | 77.92B | 151.63B | 128.60M | | Employees: | 98,213 | 99,003 | 55,200 | 81,800 | 181 | | Qtrly Rev Growth (yoy): | 8.50% | 14.90% | 1.80% | -2.90% | 14.60% | | Revenue (ttm): | N/A | 44.80B | 23.37B | 45.82B | 31.21M | | Gross Margin (ttm): | 75.20% | 76.27% | 76.36% | 86.61% | 72.61% | | EBITDA (ttm): | N/A | 17.66B | 7.81B | 21.31B | -1.65M | | Oper Margins (ttm): | N/A | 34.30% | 26.63% | 37.42% | 2.37% | | Net Income (ttm): | N/A | 8.05B | 8.05B | 8.09B | N/A | | EPS (ttm): | N/A | 3.15 | 3.808 | 1.204 | N/A | | P/E (ttm): | N/A | 13.47 | 9.70 | 15.61 | 13.73 | | PEG (5 yr expected): | 2.59 | 3.06 | 2.18 | 5.85 | 2.18 | | P/S (ttm): | N/A | 2.35 | 3.27 | 3.20 | 3.28 |
|
| GSK = GlaxoSmithKline plc | | MRK = Merck & Co. Inc. | | PFE = Pfizer Inc. | | Industry = Drug Manufacturers - Major | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.96 | 1.08% | 57.65B | 12.42 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.85 | 1.94% | 13.84B | 16.01 | | Genzyme Corp. | GENZ | 51.40 | 1.38% | 13.64B | 29.30 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.235 | 0.27% | 41.61B | 17.88 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.85 | 2.15% | 9.07B | 1037.76 | | Teva Pharmaceutical Industries Limited | TEVA | 53.63 | 1.59% | 47.25B | 49.07 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.56 | 1.27% | 3.99B | 19.36 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.88 | 0.42% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.20 | 1.85% | 5.56B | 111.66 | | Pfizer Inc. | PFE | 18.79 | 3.41% | 151.63B | 15.61 | | Johnson & Johnson | JNJ | 63.37 | 0.84% | 174.84B | 13.84 | | GlaxoSmithKline plc | GSK | 42.44 | 2.34% | 107.59B | 13.47 | | Sanofi-Aventis | SNY | 39.3505 | 3.66% | 102.75B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 56.25 | 1.17% | 127.75B | 16.84 | | RHHBY.PK | 41.41 | 1.20% | N/A | N/A | | AstraZeneca plc | AZN | 45.71 | 1.96% | 66.28B | 9.18 | | Abbott Laboratories | ABT | 54.65 | 0.29% | 84.53B | 14.81 | | Bristol-Myers Squibb Co. | BMY | 24.915001 | -1.56% | 49.36B | 12.89 |
|
| NEWS ON DIRECT COMPETITORS | |
|
|
|